Sarah Cannon - June 08, 2018

Sarah Cannon Presents Latest Cancer Research Insights at 2018 American Society of Clinical Oncology's Annual Meeting

Sarah Cannon presented its latest cancer research insights through more than 85 presentations at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting, hosted in Chicago from June 1-5, 2018.

The Annual Meeting brought together global oncology leaders to discuss “Delivering Discoveries: Expanding The Reach of Precision Medicine” and Sarah Cannon experts participated in a number of presentations and educational sessions focused on personalized medicine and targeted investigational therapies that are transforming the current and future state of cancer treatments.

“Sarah Cannon’s 25-year history has been highlighted by leading in a number of innovative areas of clinical research,” said Howard "Skip" Burris, III, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon. Dr. Burris will also serve as the ASCO® President for the 2019-2020 term. “From novel antibodies to targeted biologics, and now advancements in the field of cellular therapies, we are bringing cutting-edge treatments to patients closer to home.” 

Watch the videos below for research highlights from Sarah Cannon experts and get a glimpse of Sarah Cannon’s presence at the 54th Annual Meeting!

ASCO 2018 Recap
Sarah Cannon at ASCO 2018

Sarah Cannon Research Institute is the research arm of HCA Healthcare’s global cancer institute, Sarah Cannon. For 25 years, the organization has focused on advancing therapies for patients and has become one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes more than 275 physicians who engage in research. The organization has led more than 300 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations. For more information, visit Sarah Cannon.